Survival After Fertility-Preserving Hormonal Therapy vs Hysterectomy for Early-Stage Endometrial Cancer.

IMPORTANCE

As the number of young women with early-stage endometrial cancer is increasing, there is growing interest in use of progesterone-based therapy to allow fertility preservation.

OBJECTIVE

To ascertain the long-term survival of premenopausal women with clinical stage I endometrial cancer treated primarily with fertility-preserving hormonal therapy compared with hysterectomy.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the National Cancer Database to identify female patients aged 18 to 49 years with clinical stage I, grade 1 to 2, endometrioid endometrial cancer diagnosed from 2004 through 2020. In addition, trends in and factors associated with the use of fertility-preserving hormonal therapy were examined. Propensity score matching was used to compare survival among patients treated primarily with fertility-preserving hormonal therapy and those treated with hysterectomy. Data were analyzed from November 2023 to January 2024.

EXPOSURES

Primary treatment was defined as hysterectomy or fertility-preserving hormonal therapy based on days from diagnosis to operation or fertility-preserving hormonal therapy.

MAIN OUTCOMES AND MEASURES

Time to all-cause mortality was measured in months from cancer diagnosis to death or last follow-up at 2-year, 5-year, and 10-year intervals.

RESULTS

A total of 15 849 women, including 14 662 (92.5%) treated with primary hysterectomy (mean [IQR] age, 44 [39-47] years]) and 1187 (7.5%) who received primary hormonal therapy (mean [IQR] age, 34 [30-38] years) were identified. The use of hormonal treatment increased from 5.2% in 2004 to 13.8% in 2020 (P < .001). After propensity score matching, 5-year survival was 98.5% (95% CI, 97.3%-99.2%) for primary hysterectomy and 96.8% (95% CI, 95.3%-97.8%) for primary hormonal therapy (hazard ratio [HR] = 1.84; 95% CI, 1.06-3.21). Among patients younger than 40 years, there was no difference in survival between hysterectomy and hormonal therapy (HR = 1.00; 95% CI, 0.50-2.00). However, for patients aged 40 to 49 years, fertility-preserving hormonal therapy was associated with a significantly increased risk of death (HR = 4.94; 95% CI, 1.89-12.91).

CONCLUSIONS AND RELEVANCE

This study found that the use of fertility-preserving hormonal therapy among reproductive age patients with early-stage endometrial cancer has increased over time. While overall survival in patients with hormonal therapy is shorter than with hysterectomy, survival for patients younger than 40 years of age is comparable after primary treatment with fertility-preserving hormonal therapy or hysterectomy.